A review of international pharmacoeconomic models assessing the use of aspirin in primary prevention

References

• Leal J, Luengo-Fernandez R, Gray A, et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006;27:1610-1619
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones D, Adams R, Canethon M, et al. Heart disease and stroke statistics 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e21-181
   PubMed Web of Science ®Google Scholar
• Luengo-Fernández R, Leal J, Gray A, et al. Cost of cardiovascular diseases in the United Kingdom. Heart 2006;92:1384-1389
   PubMed Web of Science ®Google Scholar
• Pestana JA, Steyn K, Leiman A, et al. The direct and indirect costs of cardiovascular disease in South Africa in 1991. S Afr Med J 1996;86:679-684
   PubMed Web of Science ®Google Scholar
• Azambuja MI, Foppa M, Maranhão MF, et al. Economic burden of severe cardiovascular diseases in Brazil: an estimate based on secondary data. Arg Bras Cardiol 2008;91:148-155, 163-171
   PubMed Web of Science ®Google Scholar
• Zhai Y, Hu JP, Kong LZ, et al. [Economic burden of coronary heart disease and stroke attributable to hypertension in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2006;27:744-747
   PubMedGoogle Scholar
• Abegunde DO, Mathers CD, Adam T, et al. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet 2007;370:1929-1938
   PubMed Web of Science ®Google Scholar
• US Preventive Services Task Force (USPSTF). Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2009;150:396-404
   Google Scholar
• Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007;28:2375-2414
   PubMed Web of Science ®Google Scholar
• Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989;32:1129-1135
   Google Scholar
• Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988;296:313-316
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-1762
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-1304
   PubMed Web of Science ®Google Scholar
• The Medical Research Council’s General Practice Research Framework. Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233-241
   PubMed Web of Science ®Google Scholar
• Sacco M, Pellegrini F, Roncaglioni MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003;26:3264-3272
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet 2009;373:1849-1860
   PubMed Web of Science ®Google Scholar
• Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2006;98:746-750
   PubMed Web of Science ®Google Scholar
• Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306-313
   PubMed Web of Science ®Google Scholar
• World Health Organization. Prevention of Cardiovascular Disease. Guidelines for assessment and management of cardiovascular risk. 2007. Available at: http://www.who.int/cardiovascular_diseases/guidelines/Prevention_of_Cardiovascular_Disease/en/index.html. Last Accessed 01 March, 2010
   Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-2158
   PubMed Web of Science ®Google Scholar
• Khan NA, Hemmelgarn B, Herman RJ, et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2—therapy. Can J Cardiol 2009;25:287-298
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of Medical Care in Diabetes—2010. Diabetes Care 2010;33(Suppl 1):S11-61
   PubMed Web of Science ®Google Scholar
• Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134-2141
   PubMed Web of Science ®Google Scholar
• Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840
   PubMed Web of Science ®Google Scholar
• Leung WY, So WY, Stewart D, et al. Lack of benefits for prevention of cardiovascular disease with aspirin in type 2 diabetic patients—a longitudinal observational study. Cardiovasc Diabetol 2009;8:57
   PubMed Web of Science ®Google Scholar
• De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531
   PubMed Web of Science ®Google Scholar
• Zhang C, Sun A, Zhang P, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2010;77:211-218
   Google Scholar
• Calvin AD, Aggarwal NR, Murad MH, et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009;32:2300-2306
   PubMed Web of Science ®Google Scholar
• Ong G, Davis TM, Davis WA. Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: the Fremantle Diabetes Study. Diabetes Care 2010;33:317-321
   PubMed Web of Science ®Google Scholar
• Lamotte M, Annemans L, Evers T, et al. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. Pharmacoeconomics 2006;24:155-169
   PubMed Web of Science ®Google Scholar
• Lamotte M, Pinol C, Brotons C, et al. [Health economic evaluation of low-dose acetylsalicylic acid in the primary prevention of cardiovascular disease]. Rev Esp Cardiol 2006;59:807-815
   PubMed Web of Science ®Google Scholar
• Tsutani K, Igarashi A, Fujikawa K, et al. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan. Intern Med 2007;46:157-162
   PubMed Web of Science ®Google Scholar
• Benedict A, Manson SC, Pan F, et al. US budget impact of increasing low dose aspirin usage for primary and secondary prevention of cardiovascular disease. Presented at the American Heart Association Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference, Washington, DC, Apr 23--25, 2009, Poster 75
   Google Scholar
• Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 2006;368:679-686
   PubMed Web of Science ®Google Scholar
• Robberstad B, Hemed Y, Norheim OF. Cost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country – the case of Tanzania. Cost-Eff Resour Alloc 2007;5:3
   PubMedGoogle Scholar
• Greving JP, Buskens E, Koffijberg H, et al. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation 2008;117:2875-2883
   PubMed Web of Science ®Google Scholar
• Pignone M, Earnshaw S, Pletcher MJ, et al. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med 2007;167:290-295
   PubMed Web of Science ®Google Scholar
• Algra A, Greving JP. Aspirin in primary prevention: sex and baseline risk matter. Lancet 2009;373:1821-1822
   PubMed Web of Science ®Google Scholar
• Moeremans K, Lamotte M, Wittrup-Jensen K. The health economic value of aspirin in the primary prevention of cardiovascular disease in diabetic patients. Presented at the 69th Scientific Sessions of the American Diabetes Association, New Orleans, LA, Jun 5--9, 2009. Abstract 44-OR
   Google Scholar
• Franco OH, der Kinderen AJ, De Laet C, et al. Primary prevention of cardiovascular disease: cost-effectiveness comparison. Int J Technol Assess Health Care 2007;23:71-79
   PubMed Web of Science ®Google Scholar
• Pignone M, Earnshaw S, Tice JA, et al. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med 2006;144:326-336
   PubMed Web of Science ®Google Scholar
• Marshall T. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modeling study. Eur J Cardiovasc Prev Rehab 2006;13:523-528
   PubMedGoogle Scholar
• Neyt M, De Laet C, Van Brabandt H, et al. Cost-effectiveness of statins in the primary prevention of cardiovascular disease: a systematic review and economic analysis for Belgium. Acta Cardiol 2009;64:1-10
   PubMed Web of Science ®Google Scholar
• Marshall T. Coronary heart disease prevention: insights from modeling incremental cost effectiveness. BMJ 2003;327:1264
   PubMed Web of Science ®Google Scholar
• Annemans L, Lamotte M, Kubin M, et al. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation. Int J Clin Pract 2006;60:1129-1137
   PubMed Web of Science ®Google Scholar
• McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006;119:624-638
   PubMed Web of Science ®Google Scholar
• Saini SD, Schoenfeld P, Fendrick AM, et al. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention. Arch Intern Med 2008;168:1684-1690
   PubMed Web of Science ®Google Scholar
• Stafford RS, Monti V, Ma J. Underutilization of aspirin persists in US Ambulatory Care for the Secondary and Primary Prevention of Cardiovascular Disease. PLoS Med 2005;12:e353
   Google Scholar
• Gaziano TA. Reducing the growing burden of cardiovascular disease in the developing world: disease burden can be lowered with cost-effective interventions, especially by reducing the use of tobacco around the world. Health Aff (Millwood) 2007;26:13-24
   PubMed Web of Science ®Google Scholar
• Sartore ME, Kamal KM. Costs and thresholds in cost-effectiveness analysis. Aliment Pharmacol Ther 2007;26:1455-1456
   PubMed Web of Science ®Google Scholar